DarioHealth Corp. (NASDAQ:DRIO – Get Free Report)’s stock price crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.87 and traded as low as $0.59. DarioHealth shares last traded at $0.63, with a volume of 97,307 shares.
Analyst Upgrades and Downgrades
Separately, TD Cowen cut DarioHealth from a “buy” rating to a “hold” rating and dropped their price target for the company from $2.00 to $1.00 in a report on Wednesday, January 29th.
View Our Latest Stock Analysis on DRIO
DarioHealth Stock Performance
DarioHealth (NASDAQ:DRIO – Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). The firm had revenue of $7.42 million for the quarter, compared to analysts’ expectations of $7.34 million. DarioHealth had a negative net margin of 205.62% and a negative return on equity of 72.16%. During the same period in the prior year, the company posted ($0.49) earnings per share. Research analysts anticipate that DarioHealth Corp. will post -1.18 earnings per share for the current fiscal year.
Institutional Investors Weigh In On DarioHealth
Several hedge funds have recently made changes to their positions in the company. XTX Topco Ltd raised its stake in DarioHealth by 81.4% during the 3rd quarter. XTX Topco Ltd now owns 29,455 shares of the company’s stock valued at $33,000 after purchasing an additional 13,219 shares during the period. DLK Investment Management LLC grew its holdings in shares of DarioHealth by 71.6% during the third quarter. DLK Investment Management LLC now owns 100,550 shares of the company’s stock valued at $113,000 after buying an additional 41,943 shares in the last quarter. Finally, Appian Way Asset Management LP raised its position in DarioHealth by 2.5% during the third quarter. Appian Way Asset Management LP now owns 1,410,870 shares of the company’s stock valued at $1,580,000 after buying an additional 34,990 shares during the period. Hedge funds and other institutional investors own 33.39% of the company’s stock.
DarioHealth Company Profile
DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
Read More
- Five stocks we like better than DarioHealth
- Earnings Per Share Calculator: How to Calculate EPS
- 3 Must-Have ETFs Set to Dominate This Quarter
- NYSE Stocks Give Investors a Variety of Quality OptionsĀ
- Seeking Stability? These 3 Stocks Offer Strong Potential
- Short Selling – The Pros and Cons
- Trade War Bargain Stocks: Top 3 Picks Too Good to Pass Up
Receive News & Ratings for DarioHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth and related companies with MarketBeat.com's FREE daily email newsletter.